The XIENCE 28 USA Study is prospective, single arm, multi-center, open label, non-randomized
trial to evaluate safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in
subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI)
with the approved XIENCE family (XIENCE Xpedition Everolimus Eluting Coronary Stent System
[EECSS], XIENCE Alpine EECSS and XIENCE Sierra EECSS) of coronary drug-eluting stents.